737000-87-2 Usage
Uses
Used in Pharmaceutical Industry:
2,6-Diamino-3-fluoro-4-(trifluoromethyl)pyridine is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of novel drug molecules with potential therapeutic applications.
Used in Agrochemical Development:
In the agrochemical industry, 2,6-Diamino-3-fluoro-4-(trifluoromethyl)pyridine is used as a precursor in the creation of new compounds designed to protect crops and enhance agricultural productivity.
Used in Materials Science:
2,6-Diamino-3-fluoro-4-(trifluoromethyl)pyridine is employed in materials science for its potential to contribute to the development of new materials with specific properties, such as those with enhanced stability or reactivity.
Safety Note:
Due to its reactivity and potential hazards, 2,6-Diamino-3-fluoro-4-(trifluoromethyl)pyridine should be handled with care and under proper safety protocols to ensure the safety of researchers and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 737000-87-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,3,7,0,0 and 0 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 737000-87:
(8*7)+(7*3)+(6*7)+(5*0)+(4*0)+(3*0)+(2*8)+(1*7)=142
142 % 10 = 2
So 737000-87-2 is a valid CAS Registry Number.
InChI:InChI=1/C6H5F4N3/c7-4-2(6(8,9)10)1-3(11)13-5(4)12/h1H,(H4,11,12,13)
737000-87-2Relevant academic research and scientific papers
Hebeisen, Paul,Haap, Wolfgang,Kuhn, Bernd,Mohr, Peter,Wessel, Hans Peter,Zutter, Ulrich,Kirchner, Stephan,Ruf, Armin,Benz, J?rg,Joseph, Catherine,Alvarez-Sánchez, Rubén,Gubler, Marcel,Schott, Brigitte,Benardeau, Agnes,Tozzo, Effie,Kitas, Eric
, p. 3237 - 3242 (2011)
A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase.
